RPGLIFEPharmaceuticals
RPG Life Sciences Ltd — Profit & Loss Statement
₹1857.70
-2.96%
RPG Life Sciences Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 19.33 Cr | 1.48 Cr | 0.17 Cr | 0.24 Cr | — |
| Tax Rate For Calcs | 0.21 | 0.26 | 0.26 | 0.30 | — |
| Normalized EBITDA | 164.20 Cr | 129.58 Cr | 106.83 Cr | 88.55 Cr | — |
| Total Unusual Items | 90.73 Cr | 5.78 Cr | 0.66 Cr | 0.80 Cr | — |
| Total Unusual Items Excluding Goodwill | 90.73 Cr | 5.78 Cr | 0.66 Cr | 0.80 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 183.24 Cr | 87.66 Cr | 67.64 Cr | 51.48 Cr | — |
| Reconciled Depreciation | 21.43 Cr | 17.07 Cr | 15.50 Cr | 15.66 Cr | — |
| Reconciled Cost Of Revenue | 223.92 Cr | 194.20 Cr | 178.23 Cr | 150.21 Cr | — |
| EBITDA | 254.93 Cr | 135.36 Cr | 107.49 Cr | 89.35 Cr | — |
| EBIT | 233.50 Cr | 118.29 Cr | 91.99 Cr | 73.69 Cr | — |
| Net Interest Income | 1.62 Cr | -0.02 Cr | 1.58 Cr | -0.08 Cr | — |
| Interest Expense | 0.62 Cr | 0.45 Cr | 0.31 Cr | 0.52 Cr | — |
| Interest Income | 3.21 Cr | 1.42 Cr | 2.73 Cr | 1.33 Cr | — |
| Normalized Income | 111.84 Cr | 83.36 Cr | 67.15 Cr | 50.92 Cr | — |
| Net Income From Continuing And Discontinued Operation | 183.24 Cr | 87.66 Cr | 67.64 Cr | 51.48 Cr | — |
| Total Expenses | 507.17 Cr | 465.41 Cr | 420.20 Cr | 365.44 Cr | — |
| Rent Expense Supplemental | 1.07 Cr | 0.74 Cr | 0.69 Cr | 0.66 Cr | — |
| Diluted Average Shares | 1.65 Cr | 1.65 Cr | 1.65 Cr | 1.65 Cr | — |
| Basic Average Shares | 1.65 Cr | 1.65 Cr | 1.65 Cr | 1.65 Cr | — |
| Diluted EPS | 110.80 | 53.01 | 40.90 | 31.13 | — |
| Basic EPS | 110.80 | 53.01 | 40.90 | 31.13 | — |
| Diluted NI Availto Com Stockholders | 183.24 Cr | 87.66 Cr | 67.64 Cr | 51.48 Cr | — |
| Net Income Common Stockholders | 183.24 Cr | 87.66 Cr | 67.64 Cr | 51.48 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 183.24 Cr | 87.66 Cr | 67.64 Cr | 51.48 Cr | — |
| Net Income Including Noncontrolling Interests | 183.24 Cr | 87.66 Cr | 67.64 Cr | 51.48 Cr | — |
| Net Income Continuous Operations | 183.24 Cr | 87.66 Cr | 67.64 Cr | 51.48 Cr | — |
| Tax Provision | 49.64 Cr | 30.18 Cr | 24.04 Cr | 21.69 Cr | — |
| Pretax Income | 232.88 Cr | 117.84 Cr | 91.68 Cr | 73.17 Cr | — |
| Other Non Operating Income Expenses | 12.68 Cr | 7.21 Cr | 0.06 Cr | 2.99 Cr | — |
| Special Income Charges | 83.77 Cr | 0.01 Cr | -0.78 Cr | -0.09 Cr | — |
| Other Special Charges | -83.80 Cr | -0.01 Cr | 0.78 Cr | — | 0.01 Cr |
| Write Off | 0.03 Cr | 0.00 | 0.00 | 0.09 Cr | — |
| Net Non Operating Interest Income Expense | 1.62 Cr | -0.02 Cr | 1.58 Cr | -0.08 Cr | — |
| Total Other Finance Cost | 0.97 Cr | 0.99 Cr | 0.84 Cr | 0.89 Cr | — |
| Interest Expense Non Operating | 0.62 Cr | 0.45 Cr | 0.31 Cr | 0.52 Cr | — |
| Interest Income Non Operating | 3.21 Cr | 1.42 Cr | 2.73 Cr | 1.33 Cr | — |
| Operating Income | 140.37 Cr | 112.07 Cr | 88.88 Cr | 71.72 Cr | — |
| Operating Expense | 283.25 Cr | 271.21 Cr | 241.97 Cr | 215.23 Cr | — |
| Other Operating Expenses | 65.21 Cr | 63.72 Cr | 55.21 Cr | 47.42 Cr | — |
| Depreciation And Amortization In Income Statement | 21.43 Cr | 17.07 Cr | 15.50 Cr | 15.66 Cr | — |
| Amortization | 6.60 Cr | 6.66 Cr | 6.79 Cr | 6.83 Cr | — |
| Depreciation Income Statement | 14.83 Cr | 10.41 Cr | 8.71 Cr | 8.83 Cr | — |
| Selling General And Administration | 72.93 Cr | 60.90 Cr | 55.88 Cr | 53.56 Cr | — |
| Selling And Marketing Expense | 46.22 Cr | 37.85 Cr | 35.62 Cr | 32.27 Cr | — |
| General And Administrative Expense | 26.71 Cr | 23.05 Cr | 20.26 Cr | 21.29 Cr | — |
| Rent And Landing Fees | 1.07 Cr | 0.74 Cr | 0.69 Cr | 0.66 Cr | — |
| Gross Profit | 423.62 Cr | 383.28 Cr | 330.85 Cr | 286.95 Cr | — |
| Cost Of Revenue | 223.92 Cr | 194.20 Cr | 178.23 Cr | 150.21 Cr | — |
| Total Revenue | 647.54 Cr | 577.48 Cr | 509.08 Cr | 437.16 Cr | — |
| Operating Revenue | 647.54 Cr | 577.48 Cr | 509.08 Cr | 437.16 Cr | — |
| Impairment Of Capital Assets | — | — | — | — | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on RPG Life Sciences Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.